We were glad to see that the board made some of the changes we requested e.g., removing the language related to additional testing requirements for APIs in FDAs interim category 1 list
however, in clinical trials for once-daily subcutaneous administration of liraglutide 3.0 mg in patients with obesity only, or with obesity and diabetes, these effects tended to be mild-to-moderate and transient
Other studies using artificial sunlight exposure therapy during the day, with increasing morning blue-spectral illuminance peaking in the afternoon to imitate daylight for a minimum of 14 days of exposure in 4 weeks post stroke reported improved daily function through the Bartel Index and depressive test scores (Durgan et al., 2017)
If you suspect you are experiencing side effects from your medication, report them to the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)
But retatrutide goes further
Consumers should verify the current status of this proposal directly at FDA.gov before making any enrollment decision that depends on compounded GLP-1 availability
